OR WAIT null SECS
The acquisition will continue to strengthen the area of conjugate vaccines and bioconjugate drugs and will expand Biosynth’s capabilities from good manufacturing practice facilities located in Berlin, Germany.
Biosynth announced on July 11, 2023 that it has acquired celares, a leader in the development and manufacture of conjugate vaccines and bioconjugate drugs, activated PEGs, and polymer-based drug delivery excipients, according to a company press release. The acquisition will continue to strengthen the area of conjugate vaccines and bioconjugate drugs and will expand Biosynth’s capabilities from good manufacturing practice facilities located in Berlin, Germany.
“celares is an established leader in bioconjugation, and we are extremely excited to be acquiring such a great team of specialists. celares is a perfect complement to our wider business, enabling us to provide bioconjugation services and the production of PEGylation reagents and polymers for drug delivery,” said Urs Spitz, PhD, CEO and president of Biosynth, in a press release. “Together, we can support customers from development to commercialization. celares is a perfect fit for Biosynth—where chemistry meets biology.”
“We are thrilled to have joined the Biosynth group,” added Ralf Kraehmer, PhD, managing director of celares, in a press release. “As established leaders in bioconjugation, celares combines decades of chemical and biotechnological experience within the company and offers customers the possibility to access forward-looking technologies. Optimal polymer-based conjugations and formulations and manufacturing processes of drug compounds is part of our development. We see great similarities in Biosynth with their customer led strategy and passion for the life science industry.”